<i id='EB2D783821'><strike id='EB2D783821'><tt id='EB2D783821'><pre id='EB2D783821'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Alkermes shareholders re 
Prosecutors seek bail revocation for FTX founder Sam Bankman 
State Dept. review finds Biden bears some blame for Afghanistan failures 
Winning ticket for $1 billion Powerball jackpot sold in California 
Guidelines to prevent youth baseball injuries need more muscle 
Stanford president's case begs question: Who takes blame? 
Affirmative action in medical school literally saved lives 
Texas Department of Public Safety speaks out on migrant abuse allegations 
Moonlake's readout produced a cash windfall. Risks remain 
US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz 
What does generative AI mean for health care? We asked experts 
'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search
Affirmative action in medical school literally saved lives 
Taylor Swift shares sweet moment with Kobe Bryant's daughter Bianka at Eras Tour concert 
ChatGPT in medicine: STAT answers readers' burning questions 
